NASDAQ
6.15USD
+0.23 (+3.89%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
334.7M
P/E
—
EPS
—
Beta
1.11
52W range
5.85-33.68
Day range
5.88–6.32
Open
5.94
Prev close
5.92
Volume
819.9K
Avg volume
660.2K
Dividend
0.00
IPO
2024-10-11
https://www.globenewswire.com/news-release/2026/06/14/3311448/0/en/Upstream-Bio-Presents-New-Responder-Analyses-Demonstrating-Clinically-Meaningful-Improvements-in-CRSwNP-in-Significant-Majority-of-Participants-Treated-with-Verekitug-in-the-Phase-.html · 6/14/2026+1.00
https://www.globenewswire.com/news-release/2026/03/01/3246934/0/en/Upstream-Bio-Presents-Additional-Analyses-from-the-Phase-2-VIBRANT-Trial-of-Verekitug-in-Chronic-Rhinosinusitis-with-Nasal-Polyps-at-2026-AAAAI-Annual-Meeting.html · 3/1/2026+1.00
https://www.defenseworld.net/2025/12/21/upstream-bio-inc-nasdaqupb-receives-45-25-average-price-target-from-brokerages.html · 12/21/2025+0.60
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
